A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

NCT06741982 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
Lysogenic HSV Virus
Neoadjuvant Therapy
Immunotherapy
Targeted Therapy

Interventions

BIOLOGICAL: Lysogenic HSV virus.
DRUG: Tislelizumab
DRUG: Afatinib

Sponsor

West China Hospital